Company: PRTA
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001559053-25-000031
Chunk: 36

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 2
Chunk 36
---
 as compared to the recent accounting pronouncements described in our 2024 Form 10-K, that are of significance or potential significance to us.

Results of Operations

Comparison of three and six months ended June 30, 2025 and 2024

Revenue

                                                      Three Months Ended                                        Change                           
                                                      June 30,                                                                                   
                                                      2025                               2024                   $                          %     
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  (Dollars in thousands)                                                                                                                         
  Collaboration revenue                               $                       4,420      $         132,014      $           (127,594)      (97)  
  Revenue from license and intellectual property      —                                  —                      —                          —     
  Total revenue                                       $                       4,420      $         132,014      $           (127,594)      (97)  

                                                      Six Months Ended                                        Change                           
                                                      June 30,                                                                                 
                                                      2025                             2024                   $                          %     
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  (Dollars in thousands)                                                                                                                       
  Collaboration revenue                               $                     7,198      $         132,014      $           (124,816)      (95)  
  Revenue from license and intellectual property      50                               50                     —                          —     
  Total revenue                                       $                     7,248      $         132,064      $           (124,816)      (95)  

Total revenue was $4.4 million and$132.0 million for the three months ended June 30, 2025 and2024, respectively, and $7.2 million and $132.1 million for the six months ended June 30, 2025, and 2024, respectively.

Collaboration revenue was $4.4 million and $7.2 million for the three and six months ended June 30, 2025, compared to$132.0 million and$132.0 million for the three and six months ended June 30, 2024. Collaboration revenue for three and six months endedJune 30, 2025 was related to the partial performance of our PRX019 Phase 1 Clinical Trial Obligation. Collaboration revenue of$132.0 million for the three and six months ended June 30, 2024, was related to revenue recognized